# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wells Fargo analyst Tiago Fauth maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target fr...
The ruling reinforces the clear path for the U.S. Food and Drug Administration to issue a final decision on the amended New Dru...
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from...
Goldman Sachs analyst Chris Shibutani maintains United Therapeutics (NASDAQ:UTHR) with a Neutral and raises the price target...
Oppenheimer analyst Hartaj Singh maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target f...